Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genotype-guided clopidogrel monotherapy in NSTE-ACS
NCT05926271Phase 2Recruiting
- Start
- Jul 2023
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of clopidogrel in acute coronary syndrome (ACS). Primary endpoints: Primary efficacy endpoint at 6 months and Primary safety endpoint at 6 months. Started Jul 2023; status: recruiting.
02
Drugs
clopidogrel
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT05926271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05926271.